While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
With a rising number of COVID-19 cases due to the omicron variant, the FDA is making big moves. First, Pfizer's COVID-19 booster has been authorized for those ages 12 to 15. The agency also reduced the amount of time to wait between receiving a second vaccine dose and booster from six months to five. Finally, a third primary series dose of Pfizer's shot is approved for immunocompromised children five to 11 years old. Professor Peter Pitts joins Cheddar News to discuss.
California's new composting law will affect what residents do in their kitchens. As of this week, Californians will have to recycle excess food in an effort to reduce emissions caused by food waste. Cities and counties will turn recycled food into compost or use it as a renewable energy source. California's new law is the largest mandatory residential food waste recycling program in the country. Rachel Wagoner, Director of the California Department of Resources, Recycling and Recovery called the law 'the biggest change to trash' since recycling started in the 1980s. She joined Cheddar Climate to discuss.
Deborah Brosnan, President of Deborah Brosnan & Associates, joins Cheddar Climate, where she explains why global warming brought about 'a year of reckoning' in 2021 and why previously unprecedented weather events could become the norm going forward.
On this episode of Cheddar Reveals, Dr. Anita Gupta, Adjunct assistant professor of anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine, shares her forecast for the healthcare industry in 2022; Waseem Asghar, Ph.D., Associate Professor, Department of Computer & Electrical Engineering and Computer Science, Florida Atlantic University, breaks down the latest progress, trends, and innovations in wearable health tech; Cheddar gets a look at Curiosity Stream's 'Hacking our Biome.'
Dr. Anita Gupta, Adjunct assistant professor of anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine, joins Cheddar Reveals to share her forecast for the healthcare industry in 2022.
Waseem Asghar, Ph.D., Associate Professor, Department of Computer & Electrical Engineering and Computer Science, Florida Atlantic University, joins Cheddar Reveals to break down the latest progress, trends, and innovations in wearable health tech.
Washington DC and the surrounding areas saw a record breaking snow storm Monday as a strong storm system works its way across the eastern U.S. The extreme weather event caused extensive damage in the greater Washington area, leaving thousands in the region without power. Jonathan Porter, Chief Meteorologist, AccuWeather, joined Wake Up with Cheddar to discuss the fierce storm.
Sweta Chakraborty, U.S. President of We Don't Have Time and climate change expert, joins Cheddar News to discuss how mining the proper resources for the clean energy sector is crucial.
Over the past year alone, we've seen an increasing push-back on fossil fuels, legislation to reduce plastic pollution, greater protection over our worlds' forests, and a growing number of companies working to reduce total carbon footprint. To discuss the sustainability trends that defined 2021 and the changes individuals can make in 2022, J.D. Durkin is joined by Ashlee Piper, a sustainability expert and author of 'Give a Sh*t: Do Good. Live Better. Save the Planet,' joins Cheddar News.
